Syndax reports promising results from entinostat preclinical studies in breast cancer

[News]

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces results from two preclinical studies on entinostat, an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor, in animal models of breast cancer. The data are being presented as oral poster discussions at the San Antonio Breast Cancer Symposium December 8 through December 12 in San Antonio Texas.

More... (http://www.news-medical.net/news/20101213/Syndax-reports-promising-results-from-entinostat-preclinical-studies-in-breast-cancer.aspx)